H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm’s previously estimated net loss of (62c) per share, the analyst tells investors in a research note. The firm is factoring in greater operating expenses moving forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Top 3 Trending Stocks, According to Analysts – 7/11/2025
- Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts
- Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer
- Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating